David Hung, Nuvation Bio CEO

Nu­va­tion Bio shares piv­otal Chi­na da­ta for can­cer drug from An­Heart buy­out

Nu­va­tion Bio show­cased longer-term Phase 2 da­ta around the next-gen ROS1 in­hibitor it hopes will give Pfiz­er and Bris­tol My­ers Squibb a run for their …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.